Clinical Trial Record

Return to Clinical Trials

OPTimizing Treatment Focused Genetic Testing IN Cancer


2019-12-19


2022-11-30


2022-11-30


301

Study Overview

OPTimizing Treatment Focused Genetic Testing IN Cancer

This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education.

In this research study, the investigators are introducing the option of two alternatives to genetic counseling before genetic testing: Chatbot and video education. The first part of this research study is a Pilot Study, which is the first-time investigators are examining the use of a Chatbot to deliver pre-genetic test education. The Chatbot will converse with you about germline genetic testing by text message. The Pilot study will enroll 200 participants with a metastatic breast or ovarian cancer diagnosis and will assess the uptake of genetic testing among the two possible groups of pre-genetic test counseling. The second part of this research study will utilize findings from the Pilot Study for 1000 participants with a diagnosis of breast, ovarian, pancreatic or prostate cancer. In both parts of this research study, participants will be randomized to either the video education or Chatbot. Participants may request in-person genetic counseling after their respective education prior to testing. Other studies at both DFCI and outside institutions have started to investigate alternative methods of educating patients about genetic testing. These studies have suggested that alternatives to standard genetic counseling may increase access to genetic testing with similar satisfaction to standard of care. The investigators are hoping to get a sense of participants' preferences for pre genetic test education, understanding, and reactions to the alternative methods of genetic counseling. The investigators are also hoping to understand preferences for communication of their result and whether any treatment changes have been made after they receive their result.

  • Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • OTHER: Chatbot
  • OTHER: Video Education
  • 19-068

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2019-08-20  

N/A  

2024-01-24  

2019-08-22  

N/A  

2024-01-25  

2019-08-26  

N/A  

2024-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Supportive Care


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Chatbot

* Participant is given a pamphlet introducing genetic testing * Participant is given information utilized for clinical, standard of care testing. * Will receive genetic information with a virtual interactive Chatbot prior to genetic testing. After the Cha

OTHER: Chatbot

  • Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
EXPERIMENTAL: Video Education

* Participant is given a pamphlet introducing genetic testing * Participant is given information utilized for clinical, standard of care testing. * Participant will watch a brief educational video that is approximately 8 minutes in length about the geneti

OTHER: Video Education

  • Brief video designed to mirror the educational components of a traditional genetic counseling visit
Primary Outcome MeasuresMeasure DescriptionTime Frame
The measurement of genetic testing uptakeThe proportion of participants who consent to genetic testing in each study arm2 years
Meaningful cancer treatment changesAssessed by chart review. Participants with positive genetic test results will be reviewed for changes in cancer treatment.2 years
Satisfaction with pre-genetic test educationA validated survey of participants' satisfaction with the genetic counseling and testing process will be used. For the survey at the time of post-counseling, the survey for the video education arm consists of 8 questions and the genetic counseling arm contains an additional question about perceived length of the visit. The parameters for measurement are "disagree strongly", "disagree", "neither agree or disagree", "agree", and "agree strongly".at time of post-counseling/video pre-result disclosure, on average 3 weeks
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Communication of results with family membersFor those participants who have tested positive for a mutation, 5 items will be asked pertaining to disclosure of genetic testing results to relatives that are derived from previous literature.4 months post-result disclosure
Intent to disclose genetic test resultsThree items will assess participants' intentions to disclose genetic testing results1 day (at time of intervention)
Cascade testing of family membersThis will evaluate participant's discussions about genetic testing within the family for an understanding of how genetic testing information was communicated6 month post-result disclosure
Decisional regret5 items will be asked pertaining to reflecting on the decision of the participant about getting genetic testing after learning about their result.4 months post-result disclosure
Knowledge of multi-gene panel testingA 6 item survey evaluating participant's understanding of inherited genetic risk1 day (at the time of intervention)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Adult patients over the age of 18
  • With a diagnosis of advanced cancer (defined as Stage 3 or 4), or
  • Any stage for pancreatic cancer and
  • No prior cancer genetic panel testing

  • Exclusion Criteria:

  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women (if known at the time of participation)
  • Prisoners
  • Non-English speakers

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Huma Q Rana, MD, Dana-Farber Cancer Institute

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available